Adverum Biotechnologies (ADVM) PT Raised at RBC Capital To Reflect Proposed LLY Acquisition
Tweet Send to a Friend
RBC Capital analyst Lisa Walter raised the price target on Adverum Biotechnologies (NASDAQ: ADVM) to $4.00 (from $3.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
